Preoperative Pain Control in Liver Surgery Patients
Launched by EASTERN HEPATOBILIARY SURGERY HOSPITAL · Aug 14, 2013
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
Methods: In this Randomized Controlled Trial, patients undergoing partial hepatectomy will be administered a single pre-operative dose of Pregabalin or a placebo. Primary endpoints are as follows:
* Post-operative analgesic requirements
* Post-operative VAS scale (rated 0-10)
* Complications
* Post-operative antiemetic requirement
* Length of stay
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients undergoing partial hepatectomy
- Exclusion Criteria:
- • contraindication against pregabalin
- • creatinine \> 2.0 mg/dl
- • GGT \>165, AST \>105, ALT \>135
- • peptic Ulcus
- • haemorrhagic diathesis
- • angina pectoris, myocardial infarction
- • stroke
- • bronchial asthma
- • opioid abuse
About Eastern Hepatobiliary Surgery Hospital
Eastern Hepatobiliary Surgery Hospital is a premier medical institution specializing in hepatobiliary and pancreatic surgeries, renowned for its cutting-edge research and clinical excellence. With a commitment to advancing patient care through innovative surgical techniques and comprehensive research initiatives, the hospital plays a pivotal role in the development and execution of clinical trials aimed at improving outcomes for patients with liver, gallbladder, and pancreatic conditions. Its multidisciplinary team of experts collaborates to ensure rigorous adherence to ethical standards and protocols, fostering a research environment that prioritizes patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
li ai jun, MD
Study Chair
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials